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To use an umbrella review methodology to capture the range of outcomes that were associated 
with low-dose aspirin and to systematically assess the credibility of this evidence. Aspirin is 
associated with several health outcomes, but the overall benefit/risk balance related to aspirin use 
is unclear. We searched three major databases until 15th August 2019 for meta-analyses of 
observational studies and randomized controlled trials (RCTs) including low-dose aspirin 
compared to placebo or other treatments. Based on random-effects summary effect sizes, 95% 
prediction intervals, heterogeneity, small-study effects and excess significance, significant meta-
analyses of observational studies were classified from convincing (class I) to weak (class IV) 
evidence. For meta-analyses of RCTs, outcomes with random effects p-value <0.005 and  a 
moderate/high GRADE assessment, were classified as strong evidence. From 6,802 hits, 67 meta-
analyses (156 outcomes) were eligible. Observational data showed highly suggestive evidence for 
aspirin use and increased risk of upper gastrointestinal bleeding (RR=2.28, 95% CI: 1.97-2.64). In 
RCTs of low-dose aspirin, we observed strong evidence for lower risk of CVD in people without 
CVD (RR=0.83; 95%CI: 0.79-0.87) and in general population (RR=0.83; 95%CI: 0.79-0.89), 
higher risk of major gastrointestinal (RR=1.47; 9%%CI: 1.26-1.72) and intracranial bleeding 
(RR=1.34; 95%CI: 1.18-1.53), and of major bleedings in people without CVD (RR=1.62; 95%CI: 
1.26-2.08). Compared to other active medications, low-dose aspirin had strong evidence for lower 
risk of bleeding, but also lower comparative efficacy. Low-dose aspirin significantly lowers CVD 
risk and increases risk of bleeding. Evidence for multiple other health outcomes is limited. 
 






Low-dose aspirin, defined as less than 325 mg daily, is widely-used worldwide, particularly for 
cardiovascular disease (CVD) prevention [1]. The United States Preventive Services Task Force 
(USPSTF) recommends aspirin for primary CVD prevention in adults with a 10-year risk of heart 
attack or stroke exceeding 10% in individuals who are not at increased risk of bleeding and after 
individualised informed decisions [2, 3], whilst other societies recommend low-dose aspirin use 
for secondary CVD prevention only [4]. In the US, over 30% of adults take aspirin for CVD 
prevention, but use in recent years is probably decreasing [4]. 
 
Aspirin irreversibly inhibits cyclo-oxygenase 1 (COX-1) which leads to inhibition of platelet 
thromboxane A2 and thrombus formation in arteries [5]. Beyond CVD, low-dose aspirin use has 
been linked to lower risk of cancers, overall mortality and other chronic conditions [4]. The 
veracity of these claimed non-cardiovascular effects is unclear. European and American guidelines 
currently do not support aspirin for cancer prevention [4, 6], but the issue is unsettled [7, 8]. 
However, despite possible benefits, low-dose aspirin is also associated with an increased risk of 
bleeding [9] and any clinical benefits needs to be balanced with adverse effects. At the same time, 
prescription of low-dose aspirin in many primary care settings is suboptimal [10, 11] and many 
patients who would probably benefit remain untreated [12]. Improving appropriate use of aspirin 
is therefore essential [11]. The research body on low dose aspirin is constantly increasing with new 
studies and meta-analyses thereof being published during the last few years. At the same time, the 
breadth of outcomes examined has expanded to cover a wide range of outcomes not limited to 
cardiovascular disease. We used the umbrella review methodology in order to capture the breadth 
of outcomes reported and assess the totality of evidence of low dose aspirin on a number of 
outcomes [13]. In this sense, umbrella reviews (i.e. reviews of previously published systematic 





statistical approach for all factors to allow their comparison) have been created for overcoming the 
inherent limitations of meta-analyses. [13] 
 
Here we aimed to capture the breadth of outcomes that have been associated with low-dose aspirin 
intake and systematically assess the quality, strength and credibility of the associations. We used 
the umbrella review methodology to combine evidence from a wide range of outcomes and 
populations and we present results separately for observational studies and randomised controlled 






Data sources and searches 
We conducted an umbrella review [14], searching the MEDLINE, Scopus, Embase databases from 
inception until 15th August 2019 with: “(Meta-Analysis[ptyp] OR metaanaly*[tiab] OR meta-
analy*[tiab] OR Systematic review [ptyp] OR “systematic review” [tiab]) AND (aspirin [tiab])”. 
In addition, we hand-searched the reference lists of eligible articles.  
 
Study selection 
Eligible articles were systematic reviews with meta-analyses of observational/intervention studies, 
which investigated low-dose aspirin in relation to any clinical outcome. Four authors (JD, GP, TB, 
SC) independently performed title and abstract screening in couples. Disagreements were resolved 
through consensus with another independent author (NV). Full-texts of all potentially eligible 
articles were then retrieved by the same four authors and any disagreement was resolved with 
another independent author (MS).  
 
We included meta-analyses that investigated effects of low-dose aspirin, defined as least 75mg 
and less than 325mg daily [15, 16] or use of the regular 325 mg aspirin dose three or more times 
a week (but not daily) for at least six months [17]. Both meta-analyses of observational studies 
that investigated the association of low-dose aspirin with any clinical outcome and meta-analyses 
of RCTs were considered. Meta-analyses were included only if they reported study-specific 
information (i.e. effect size, 95% confidence intervals [CIs], sample size) or if those metrics could 
be inferred from the data presented. The RCT meta-analyses were divided in meta-analysis of 
placebo/no active control and active control groups (e.g. heparins, vitamin K antagonists).  Studies 
were excluded if aspirin was accompanied by additional co-administered medications (e.g. 







Four independent investigators (JD, GP, TB, SC), extracted the following information for each 
meta-analysis, independently, in pairs: first author name; publication year; number of studies; 
study population; type of effect size; study design; number of participants with (cases) and without 
(controls) events for each study. We also extracted the study-specific estimated relative risk for 
health outcome (risk ratio, RR; odds ratio OR; hazard ratio, HR; mean difference, MD; 
standardized mean difference, SMD) and 95% CIs. We finally extracted the data for the 
Assessment of Multiple Systematic Reviews (AMSTAR)-2 tool [18].  
 
When more than one meta-analysis on the same research question using the same study design 
(observational or RCTs) was identified, the one with the largest number of participants was 
selected. 
 
Data synthesis and analysis 
For each meta-analysis, we estimated the summary effect size and its 95% CI by using the random-
effects Hartung-Knapp-Sidik-Jonkman (HK) estimator [19]. This estimator consistently results in 
more adequate error rates than the DerSirmonian-Leird method, especially when the number of 
studies is small [19].  We also estimated the prediction interval (PIs) and its 95% CI, which further 
accounts for between-study effects and estimates the certainty of the association if a new study 
addresses that same association [20-22]. In order to estimate whether any large studies were 
available, for the largest study of each meta-analysis, we calculated the standard error (SE) of the 
effect size. If the SE was less than 0.10, then the 95% CI would be lower than 0.20. Between-study 
inconsistency was estimated with the I2 metric, with values > 50% indicative of high heterogeneity 
[23].  
We calculated the evidence of small-study effects (i.e. whether small studies inflated effect sizes) 





Finally, we applied the excess of significance test [26]. Because of the limited statistical power of 
this test, a lenient significance threshold (p < 0.10) was adopted [27]. We considered the effect 
size of the largest dataset and based on this we estimated the power of each constituent study with 
an algorithm using a non-central t distribution. Excess significance for each meta-analysis was 
considered whenever p < 0.10. 
 
All statistical analyses were conducted in Stata, version 14.0 (StataCorp), and R, version 3.3.0 (R 
Foundation for Statistical Computing). 
 
Grading the evidence 
For observational studies, using the criteria mentioned above, significant associations (i.e. p<0.05) 
were categorized into strong, highly suggestive, suggestive, or weak evidence, following a grading 
scheme that has already been applied in various fields [28-35], as reported in Table 1. We assessed 
the methodological quality of the included meta-analyses of observational studies using 
AMSTAR-2 [18, 36] that ranks the quality of a meta-analysis from critically low to high according 
to 16 predefined items. For each association in the convincing or highly suggestive categories we 
reassessed the evidence keeping only prospective observational studies in an attempt to address 
reverse causality and applying the credibility ceiling at 10%. However, application of the 10% 
credibility ceiling did not affect any class I associations. Finally, for each association in the 
convincing category, we reassessed the evidence taking in account the AMSTAR-2 evaluation. 
 
Evidence from meta-analyses of RCTs was assessed in terms of the significance of the summary 
effect, using a p-value <0.005 as the threshold for statistical significance, as recently proposed [37, 
38]. We used stringent p-values when evaluating the findings of RCTs in order to decrease the 
possibility of ‘false-positives’ (i.e. to claim that an effect is present when there is none in reality) 





GRADE (Grading of Recommendations, Assessment, Development and Evaluation) assessment 
[40]. Outcomes having a p-value <0.005 and a moderate/high GRADE assessment, were classified 
as strong evidence. We also considered  95% PIs (excluding the null or not), the presence of large 
heterogeneity (I2 >50%), small study effects (P>0.10), and excess significance (P>0.10) as possible 







Overall, we identified 6,802 papers (Figure 1); 578 publications were selected as potentially 
eligible and 67 meta-analyses (corresponding to 156 different outcomes) were finally included in 
this study (references in Supplementary Material). 
 
Meta-analyses of observational studies 
The median number of studies of meta-analyses including observational studies for each outcome 
was 3 (range 2-32), the median number of participants was 11,894 (range 520 to 1,059,682), and 
the median number of cases was 1,114 (range 10 to 144,373) (eTable 1).  
 
The majority of the meta-analyses included studies on general populations, followed by patients 
with cancer or diabetes. Overall, 11 out of the 41 outcomes reported nominally significant 
summary results (p<0.05), but only two associations survived the application of the more 
stringent p-value (P < 10−6), i.e. higher risk of upper gastrointestinal bleeding in general population 
and in people undergoing coronary artery bypass graft.   
 
The study with the largest number of participants included had a SE of less than 0.10 in 12 
outcomes and a more conservative effect compared to the random-effects model in 11 of these 12 
outcomes. Heterogeneity among studies was modest and 24 outcomes presented low heterogeneity 
(I2<50%). Three associations presented 95% PIs excluding the null value. Evidence for excess 
statistical significance was present in 5/41 outcomes and small-study effects were also seen in 5/41 
of the outcomes. Publication bias was present in 6/41 outcomes.  
 
Based on the above criteria, no outcome presented convincing evidence, only one outcome 





in the general population; RR=2.28, 95% CI: 1.97-2.64), two outcomes presented suggestive 
evidence (class III: lower incidence of prostate cancer and cancer specific death in the general 
population) and 8 outcomes a weak evidence. Using the AMSTAR-2, all the meta-analyses 
included were evaluated as having a critically low rating mainly because the risk of bias was not 
accurately assessed and the sources of funding for the included studies was not reported (eTable 
2).  
 
In a sensitivity analysis, we included only prospective cohort studies in each meta-analysis (eTable 
3). Two outcomes presented suggestive evidence (lower cancer-specific death in people affected 
by colorectal cancer and higher risk of upper gastrointestinal bleeding in the general population) 
and four were classified as weak evidence. Both outcomes with suggestive evidence had a low 
AMSTAR-2 score.  
 
Meta-analyses of RCTs (vs. placebo/no treatment) 
The median number of RCTs meta-analyses using placebo/no treatment for each outcome was 5 
(range 2-23), the number of participants was, in median, 12,184 (71 to 1,126,384), and the median 
number of cases was 377 (4 to 7,087) (eTable 4).  
 
Overall, 76 outcomes were included. Of them, 25 outcomes reported significant results (p<0.05), 
but only five survived the application of a more stringent p value (p<0.005): lower risk of serious 
CVD in people without CVD (RR=0.83; 95%CI: 0.79-0.87) and of CVD in general population 
(RR=0.83; 95%CI: 0.78-0.89), higher risk of major gastrointestinal (RR=1.47; 9%%CI: 1.26-1.72) 
and intracranial bleeding (RR=1.34; 95%CI: 1.18-1.53) in general population, and major bleedings 
in people without CVD at baseline (RR=1.62; 95%CI: 1.26-2.08). Using the GRADE assessment, 





having a p-value <0.005, except for major bleeding in primary prevention (presence of publication 
bias).  
 
The largest study, in terms of sample size, had a SE of less than 0.10 in only 15 outcomes. 
Heterogeneity among studies was low in 60/76 studies, with 40 reporting an I2=0%. Nine outcomes 
presented 95% prediction interval excluding the null value. Finally, evidence for excess statistical 
significance was present in 5/74 outcomes and small-study effects were present in 6/76 outcomes.  
 
As reported in eTable 5, only 2/76 rated “high”, 6 rated “low” according to the AMSTAR-2 
criteria, whilst the other meta-analyses were rated as “critically low”.  
 
Meta-analyses of RCTs (vs. active controls) 
As reported in eTable 6, the median number of studies of meta-analyses including intervention 
studies using active controls for each outcome was 3 (range 2-15), the median number of 
participants was 3,607 (193 to 33,435), and the median number of cases was 121 (4 to 1,364).  
 
In these meta-analyses, 16 (41%) out of the 39 outcomes reported nominally significant summary 
results (p<0.05), and, of them, two treatment effects had a summary effect with a p-value <0.005 
(Table 3). Using the GRADE assessment, we observed strong evidence for associations between 
aspirin use and higher risk of subarachnoid bleeding in cerebrovascular conditions (compared to 
cilostazol) and higher incidence of pulmonary embolism in cancer under chemotherapy (compared 
to heparins). Three meta-analyses were rated as low quality according to the criteria suggested by 
the AMSTAR-2, the others critically low (eTable 7).   
 
Heterogeneity among studies was low, with the majority of outcomes (32/39) (82%) having an 





interval excluding the null value. Only one study showed evidence for excess significance, whilst 
no outcomes showed evidence for statistically significant small-study effects. No meta-analysis 
had evidence for publication bias.  
 
Comparison of findings from observational studies and clinical trials 
As reported in eTable 8, ten outcomes were examined by both meta-analyses of observational 
studies and meta-analyses of RCTs using placebo/no intervention as controls.  
The direction of the association/effect was concordant for seven of the 10 outcomes. In one case 
(stroke in patients with type 2 diabetes), the 95% CIs of RCTs excluded the null from the estimated 
effect size, but they were in the opposite direction, while in the other nine topics, the 95% CIs 






With this work, we provide a comprehensive overview of the associations between low-dose 
aspirin and a wide range of health outcomes.  
 
In a large epidemiological study, it is reported that about one third of American people take low-
dose aspirin for primary and secondary prevention, even if the prevalence of people taking aspirin 
is declining in the last years [41]. In a more recent study, a consistent part of American people  
were taking aspirin without a physician's recommendation, corresponding to about 6.6 million 
adults. Nearly half of people at least 70 years of age in the survey, 44.6%, were on aspirin for 
primary CVD prevention [42]. Therefore, to systematically know the efficacy and the risk of low-
dose aspirin use is of great clinical importance.  
 
The topic of the use of low-dose aspirin in primary prevention is of great interest. Our umbrella 
review found that for primary prevention, use of low-dose aspirin was associated with 17% lower 
CVD incidence (including serious events, i.e. non-fatal myocardial infarction, non-fatal stroke, or 
vascular death). Moreover, low-dose aspirin was associated with 34% higher risk of bleeding in 
primary prevention (major and intracranial). These risks and benefits need to be weighted in formal 
decision analysis to guide aspirin use in primary prevention. Taken together, these findings suggest 
that in the balance between prevention and risk one should consider the risk of bleedings. Three 
recent RCTs were published last year [43-45]. The ARRIVE (Aspirin to Reduce the Risk of Initial 
Vascular Events) trial enrolled  participants at high risk for CVD events without diabetes [43]. The 
results of this trial suggested no significant effect of low-dose aspirin on the reduction of CVD 
incidence, but a significantly increased risk of gastrointestinal bleedings [43]. Another recent 
randomized controlled trial, the ASCEND study (A Study of Cardiovascular Events in Diabetes), 
documented a significant benefit of aspirin among people with diabetes in preventing CVD events 





in a manner similar to our findings. In a third randomized controlled trial, data from ASPREE 
(Aspirin in Reducing Events in the Elderly) showed no benefit of aspirin on CVD events in older 
people and also demonstrated a significantly increased risk of major bleeding in those taking 
aspirin in this older age group. [45]. Taken together these findings and those from the present 
umbrella review, suggest that the benefits and risks of low-dose aspirin for the primary prevention 
of CVD events in the modern era of preventive management in middle-aged people (i.e., involving 
statins, anti-hypertension medications, smoking cessation, obesity management and other similar 
interventions) are closely balanced, calling into question the use of aspirin in those without a prior 
cardiovascular disease event. 
 
A topic of great clinical relevance in clinical settings is low-dose aspirin in primary prevention 
specifically for those at high CVD risk, such as people with diabetes. Observational and 
intervention studies in this review show little evidence that low-dose aspirin prevents overall and 
specific CVD events in diabetes (eTable 1) indicating that the widespread use of this medication 
may not be justified in this population. [46]. As shown in eTable 9, these findings can be applied 
in other conditions at higher risk of CVD such as women with antiphospholipid antibodies. 
Unfortunately, we were not able to do the same considerations for secondary prevention due to the 
limited data available.  
 
The prevention of cancer is another topic of interest [47]. In our umbrella review, we identified 
several meta-analyses including observational studies, which investigated the effect of aspirin on 
risk of cancer/cancer progression/cancer specific death. Low-dose aspirin was associated with a 
reduced risk of prostate cancer with a suggestive evidence in observational studies, whilst the 
evidence regarding mortality in colorectal cancer patients was weak. The USPSTF guidelines 
suggested that low-dose aspirin is efficacious in reducing the incidence of colorectal cancer, even 





was not eligible for  our umbrella review, since, among four studies eligible, two studies used 
doses of aspirin > 325 mg and another one used a vitamin supplementation together with aspirin 
[47]. Other guidelines specifically from cancer related societies suggest that low-dose aspirin 
should be not used in general population, but only in some specific conditions, such as Lynch’s 
syndrome [48].  In meta-analyses of the RCTs (vs. placebo/no intervention), low-dose aspirin was 
associated with a nominally statistically significant reduction in cancer-specific death in people 
affected by cancer at baseline or in the general population, but this evidence remains poor.  
 
As reported in eTable 9, we found, in observational studies, highly suggestive evidence or at least 
suggestive evidence that low-dose aspirin is associated with a higher risk of upper and overall 
gastrointestinal bleeding in the general population, i.e. in primary prevention setting. The risk of 
these events is more than doubled compared to no users [49], an observation confirmed in the 
RCTs versus placebo/no intervention. However, the risk of bleeding (overall, major, 
gastrointestinal) was lower in people taking low-dose aspirin compared to several other 
medications, including clopidogrel.  
 
Our study has some shortcomings that we should acknowledge. First, we used evidence assessment 
criteria, which can be biased, being based on already established tools for observation and 
interventional studies [33, 50]. Moreover, since the meta-analyses included studies with significant 
differences in design, population and other basic characteristics, large heterogeneity may be 
worrisome. We consequently used an I2<50% as one of the criteria for having convincing 
outcomes. However, I2 estimates can also carry substantial uncertainty [51] and often clinical 
heterogeneity might be of importance, even in the absence of statistical heterogeneity. It is known 
that meta-analyses have important limitations [52] and their results may also depend on choices 
made about what estimates to select from each study and how to report them in the meta-analysis 





dosage) [53]. Applying the criteria suggested by the AMSTAR-2 for evaluating the quality of 
meta-analyses, we observed the presence of low/critically low rating. This evidence is mainly due 
to missing information in item 2 (protocol published before the meta-analysis), 7 (list of excluded 
studies), or 11 (no appropriate meta-analytic approach, particularly the absence of investigation in 
case of high heterogeneity).  Furthermore, low-dose aspirin covers a substantial range of dosing 
regimens and these may not have exactly the same efficacy and harms, but this was beyond the 
discerning ability of our study design [54]. The umbrella review was limited to outcomes studied 
in the respective meta-analyses and does not provide in-depth data on disease severity, dose-
response effects, or specific subgroups such as by sex or age. At the same time, it is also possible 
that some studies were included in two or more outcomes (e.g. in intracranial and major bleedings) 
in major bleeding that is a cumulative outcome: however, we believe that this includes a limited 
portion of the studies included, over 156 outcomes. We decided to include the data from 
observational studies that are, per se, biased in their nature. As a number of outcomes (34/41) were 
only examined in observational settings, we included in this review data from observational studies 
acknowledging their limitations. However, a large majority of the outcomes included in the 
observational studies (34/41) were not included in those of RCTs, highlighting the importance of 
their inclusion. Finally, this umbrella review could not explore fully the possibility of risk 
stratification for clinical use, especially taking into account potential risk factors for adverse 
outcomes. 
 
In conclusion, in this umbrella review including 67 independent meta-analyses and 156 outcomes, 
we found that low-dose aspirin decreased the risk of CVD events in the general population (when 
compared to placebo/no intervention) with strong evidence according to GRADE criteria, whilst 
the data for individual CVD outcomes are limited. Moreover, when limiting to only observational 
studies, moderate evidence for associations between aspirin intake and lower risk of specific 





caution given the inherent bias of observational study designs. The risk of bleeding (particularly 
gastrointestinal and intracranial) is, however, also strong and substantial, suggesting that 
physicians should accurately consider the risks and benefits of prescribing aspirin. Despite many 
dozens of other clinical outcomes having been assessed, evidence for them remains weak and 
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Figure 1. Flow-chart  
 
 
 
